Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Astellas Pharma Inc patents


Recent patent applications related to Astellas Pharma Inc. Astellas Pharma Inc is listed as an Agent/Assignee. Note: Astellas Pharma Inc may have other listings under different names/spellings. We're not affiliated with Astellas Pharma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Astellas Pharma Inc-related inventors


 new patent  Dosage regimen for a tiacumicin compound

The present inventors provides one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof for use in the oral treatment of clostridium difficile infections (cdi) or clostridium difficile-associated disease (cdad) in a patient according to a dosage regimen comprising: (1) administering to the patient in an initial course of treatment 200 mg of the tiacumicin compound twice a day; (2) monitoring the efficacy of the initial course of treatment in the patient by means of monitoring changes of one or more indicators of cdi or cdad; (3) assessing whether there is a positive change of the one or the more of the indicators; and (4) switching to an intermittent course of treatment by administering to the patient 200 mg of the tiacumicin compound every other day if the one or the more of the indicators of cdi or cdad are positively changed. Further the invention provides the use of the tiacumicin compound to reduce recurrence in a patient suffering from cdi or cdad.. ... Astellas Pharma Inc

Granular pharmaceutical composition

. . The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.. ... Astellas Pharma Inc

Stable pharmaceutical composition for oral administration

Provided is a stable pharmaceutical composition for oral administration comprising 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2h-pyran-4-ylamino)pyrazine-2-carboxamide (hereinafter referred to as compound a) or a pharmaceutically acceptable salt thereof, wherein the generation of related substances during storage is inhibited. In the stable pharmaceutical composition for oral administration, the proportion of crystals of compound a or a pharmaceutically acceptable salt thereof is 60% or more with respect to the total amount of compound a or a pharmaceutically acceptable salt thereof.. ... Astellas Pharma Inc

Production method of enzalutamide crystal form

. . . . The present invention aims to provided a novel production method of an enzalutamide crystal form in which wet crystals of enzalutamide are obtained in a step of crystallizing in the production process of the enzalutamide crystal form, and then 2-propanol which is solvated with enzalutamide and the b-type crystals are reduced. The present invention relates to a production method of an enzalutamide crystal form, which comprises a step of crystallizing for obtaining wet crystals of enzalutamide, and a step of drying the wet crystals, and comprises a step of washing using a mixed solvent of a good solvent and a poor solvent after the step of crystallizing.. ... Astellas Pharma Inc

Stabilized pharmaceutical composition

Provided is a pharmaceutical composition, which comprises 5-{[(3r)-1-acryloylpyrrolidin-3-yl]oxy}-6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-pyrazine-2-carboxamide (hereinafter referred to as “compound a”) or a pharmaceutically acceptable salt thereof, and is stabilized. The pharmaceutical composition comprises compound a or a pharmaceutically acceptable salt thereof, and a pharmaceutical additive having a difference in water activity value of 0.1 or more, and is stabilized.. ... Astellas Pharma Inc

Pharmaceutical composition for oral administration

Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2r)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having ph-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.. ... Astellas Pharma Inc

Pharmaceutical composition containing mirabegron

To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.. ... Astellas Pharma Inc

2-aminothiazole derivative or salt thereof

. . . . . . . . . . . . A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic m3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic m3 receptor, thereby completing the present invention. ... Astellas Pharma Inc

Novel anti-human tie-2 antibody

Provided is an anti-human tie2 antibody for preventing or treating diabetic macular edema, diabetic retinopathy, and critical limb ischemia by binding to a human tie2 to activate the human tie2. The present inventors have conducted investigations on an anti-human tie2 antibody, and have thus provided an anti-human tie2 antibody comprising four heavy chain variable regions and four light chain variable regions, in which the heavy chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 122 of seq id no: 2, the light chain variable region consists of the amino acid sequence of the amino acid numbers 1 to 113 of seq id no: 4, the one heavy chain variable region and the one light chain variable region constitute one antigen-binding site, and the antibody comprises four antigen-binding sites.. ... Astellas Pharma Inc

Pharmaceutical composition for modified release

A pharmaceutical composition for modified release, comprising (1) (r)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 ml or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mpa·s or more at a 5% aqueous solution at 25° c. Is disclosed.. ... Astellas Pharma Inc

Formulations of enzalutamide

. . This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.. . ... Astellas Pharma Inc

Granular pharmaceutical composition

. . . . The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.. ... Astellas Pharma Inc

System and method for analyzing adverse event data

. . A non-transitory memory is configured to store adverse event data. The adverse event data describes whether an individual experienced an adverse event as a result of being administered a therapeutic agent on each day during a time period. ... Astellas Pharma Inc

Formulations of enzalutamide

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.. . ... Astellas Pharma Inc

01/19/17 / #20170014632

Method for treating premature ejaculation and method for controlling premature ejaculation treatment device

Methods of treating premature ejaculation include arranging one or more electrodes to face dorsal penile nerves (dpns) of a patient with premature ejaculation, and applying an electro stimulation having a frequency and a current by which seminal fluid expulsion is not induced in the patient by the one or more electrodes during a time period from before the start of sexual intercourse to ejaculation. The electro stimulation reversibly extends an intravaginal ejaculatory latency time (ielt) of the patient. ... Astellas Pharma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Astellas Pharma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Astellas Pharma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###